SCA
RNAM

Snowden Capital Advisors’s Avidity Biosciences RNAM Stock Holding History

Snowden Capital Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,535
Closed -$503K – 1321
2025
Q3 		$503K Buy
11,535
+2,719
+31% +$110K 0.01% 773
2025
Q2 		$250K Sell
8,816
-51
-0.6% -$1.52K 0.01% 1080
2025
Q1 		$262K Buy
+8,867
New +$276K 0.01% 1043
2024
Q4 		– Sell
-4,654
Closed -$214K – 1254
2024
Q3 		$214K Buy
+4,654
New +$202K 0.01% 1146

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Snowden Capital Advisors's RNAM Position: Q4 2025 in Review

Snowden Capital Advisors sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 11,535 shares — an estimated $503K sold.

Snowden Capital Advisors first reported a position in RNAM in Q3 2024 and held it in 4 quarters. The position peaked at $503K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Snowden Capital Advisors reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Snowden Capital Advisors sold 11,535 Avidity Biosciences shares in Q4 2025, an estimated $503K.
  • Snowden Capital Advisors first reported a position in Avidity Biosciences in Q3 2024 and held it in 4 quarters.
  • Snowden Capital Advisors's Avidity Biosciences position peaked at $503K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Snowden Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.